The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for certain activity generated through this link. Prices displayed are informational.

Our analysts just identified a stock with the potential to be the next Nvidia. Tell us how you invest and we'll show you why it's our #1 pick. Tap here.

Achieved positive EBITDA in Q2 2026, driven by a 23% year-over-year increase in total net product revenue while maintaining flat operating expenses.

Amrozi revenue reached $8.1 million, fueled by a 20% sequential increase in total prescriptions and a significant expansion of the unique prescriber base to over 4.5 thousand.

Performance attribution is centered on Amrozi's superior head-to-head efficacy data against Oracea, which management reports is driving high patient satisfaction and rapid clinical onset.

Improved profitability was supported by a rising Average Selling Price (ASP) as the company successfully transitioned more prescriptions to reimbursed channels.

Strategic commercial expansion included hiring five additional dermatology sales professionals to target white space and high-density territories.

Market access improved as high-quality formulary coverage (single step-edit or better) reached 38% of commercial lives, up from 34% in the previous quarter.

Management expects 2026 to be a 'breakout year' with sustainable EBITDA and cash flow positivity projected for the remainder of the year.

ASP is anticipated to continue its upward trajectory through the second half of 2026 as recent national health plan additions begin to impact the business mix.

Future growth will be supported by the launch of Urox Cream, a non-steroidal anti-itch product deployed to the sales force in July 2026.

Strategic focus remains on converting the remaining 80-90 million commercial lives with access from high-friction status (prior authorizations) to high-quality coverage.

The company is actively pursuing out-licensing opportunities for patented products in non-U.S. territories and exploring potential in-licensing of new dermatology assets.

SG&A expenses decreased year-over-year primarily due to the absence of one-time launch-related spending for Amrozi incurred in Q2 2025.

Management noted that while QBREXZA revenue can fluctuate due to payer mix and deductible resets, demand remains strong with July prescriptions nearing 15 thousand.

The company successfully integrated with all top three GPOs, providing planned access to 169 million out of 192 million covered commercial lives in the U.S.

One stock. Nvidia-level potential. 30M+ investors trust Moby to find it first. Get the pick. Tap here.

Management confirmed there were no inventory movements inflating Q2 results and expressed confidence in sequential ASP gains through the end of the year.

Growth is expected to stem from the implementation of new payer strategies and increased reimbursement from insurance companies.

Management indicated that while winter weather can impact rosacea, the market remains largely consistent, and they do not anticipate significant seasonality.

July data showed continued momentum with approximately 14 thousand total prescriptions, maintaining the upward trend from June's all-time high.

The primary bottleneck is the 'delta' of approximately 80-90 million lives that have access but face high friction like double-step therapy or prior authorizations.

Management is leveraging Amrozi's 8-week efficacy data (versus 16 weeks for competitors) to negotiate the removal of these clinical and financial barriers.

The five new sales representatives are a mix of white space hires and territory splits in high-penetration areas.

Physicians are primarily utilizing Amrozi for moderate-to-severe papulopustular rosacea, citing the superior safety profile and clearance rates as key drivers.